COVID-19 and stroke
Due to the pandemic of corona virus disease 2019 (COVID-19), the stroke medical care system is unavoidably undergoing major changes such as a decrease in the number of stroke patients receiving consultation, delay in consultation, and a decrease in the number of intravenous thrombolysis and mechanical thrombectomy procedures. Stroke incidence in COVID-19 patients is approximately 1.1%. The features of stroke with COVID-19 have been elucidated: higher incidence in ischemic stroke than hemorrhagic stroke, increasing number of young patients, high D-dimer levels, and higher risk in elderly patients with cardiovascular risk factors such as hypertension and diabetes. In patients with COVID-19, venous thromboembolism is more common than arterial thromboembolism, and stroke is more common than acute coronary syndrome. Protected code stroke (PCS) has been proposed which provides safe, effective and prompt treatment under complete infection control.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Rinsho shinkeigaku = Clinical neurology - 60(2020), 12 vom: 26. Dez., Seite 822-839 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Wada, Kuniyasu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 15.01.2021 Date Revised 15.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5692/clinicalneurol.cn-001529 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317967568 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317967568 | ||
| 003 | DE-627 | ||
| 005 | 20231225164353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.5692/clinicalneurol.cn-001529 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1059.xml |
| 035 | |a (DE-627)NLM317967568 | ||
| 035 | |a (NLM)33229838 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Wada, Kuniyasu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and stroke |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2021 | ||
| 500 | |a Date Revised 15.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Due to the pandemic of corona virus disease 2019 (COVID-19), the stroke medical care system is unavoidably undergoing major changes such as a decrease in the number of stroke patients receiving consultation, delay in consultation, and a decrease in the number of intravenous thrombolysis and mechanical thrombectomy procedures. Stroke incidence in COVID-19 patients is approximately 1.1%. The features of stroke with COVID-19 have been elucidated: higher incidence in ischemic stroke than hemorrhagic stroke, increasing number of young patients, high D-dimer levels, and higher risk in elderly patients with cardiovascular risk factors such as hypertension and diabetes. In patients with COVID-19, venous thromboembolism is more common than arterial thromboembolism, and stroke is more common than acute coronary syndrome. Protected code stroke (PCS) has been proposed which provides safe, effective and prompt treatment under complete infection control | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a cryptogenic stroke | |
| 650 | 4 | |a large vessel occlusion | |
| 650 | 4 | |a protected code stroke | |
| 650 | 4 | |a stroke | |
| 650 | 7 | |a Fibrin Fibrinogen Degradation Products |2 NLM | |
| 650 | 7 | |a fibrin fragment D |2 NLM | |
| 700 | 1 | |a Hashimoto, Yoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda, Mitsuharu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho shinkeigaku = Clinical neurology |d 1972 |g 60(2020), 12 vom: 26. Dez., Seite 822-839 |w (DE-627)NLM000226874 |x 1882-0654 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2020 |g number:12 |g day:26 |g month:12 |g pages:822-839 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5692/clinicalneurol.cn-001529 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2020 |e 12 |b 26 |c 12 |h 822-839 | ||